Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic
cardiovascular disease (myocardial infarction,
stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels.
